Reviewer's report

Title: Favorable Response to Pembrolizumab after Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report

Version: 0  Date: 05 Dec 2019

Reviewer: Christian Caglevic

Reviewer's report:

Dear Authors:

After reviewing your manuscript I believe it is a nice case to be reported, however I think it is necessary to change the focus from NSCLC to Sarcomatoid Carcinoma of the Lung

Despite Sarcomatoid Carcinoma of the lung is classified as NSCLC it is a rare entity and has a different development and prognosis than adenocarcinoma and squamous lung cancer

I suggest to consider the next reference to improve your manuscript:


I suggest to change the title: Favorable Response to Pembrolizumab after Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case report

In Background:

It is not clear when you mention that treatments after Durvalumab progression are unknown, if you talk about as which treatment you will prescribe or if you are thinking about Pacific trial patients that underwent Durvalumab treatment. Patients that had treatment after Durvalumab in this trial are described in the supplementary appendix of your reference 1

In Discussion and Conclusions:

- you say "the possibility of pseudoprogression cannot be denied", I think by reading your report that it is clear a disease progression after durvalumab. Please consider to change this part
- In Antonia`s paper (Pacific trial) no cases of sarcomatoid carcinoma were reported (we do not know if any was included or not) but I think it is important to clarify this issue in your manuscript

- In this same paper reported PD-L1 \( \geq 25\% \) in the Durvalumab arm was 32\% but we do not know the proportion of patients \( \geq 50\% \). I think it is important this idea to be included in your discussion

- Your conclusions should be focussed in sarcomatoid carcinoma rather than NSCLC in general

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Unable to assess

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

No

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal